Kolexia
Deluche Elise Oncologie médicale
Deluche Elise
Oncologie médicale
Hôpital Dupuytren
Limoges, France
227 Activités
643 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Sarcopénie Carcinomes Métastase tumorale Tumeurs du sein triple-négatives Récidive tumorale locale Glioblastome Tumeurs du cerveau Tumeurs de l'ovaire

Collaborateurs

Voir plus
Venat Laurence
Venat Laurence
Hôpital Dupuytren, Limoges, France
Ladoire Sylvain
Ladoire Sylvain
Centre Georges-François Leclerc, Dijon, France
Tredan Olivier
Tredan Olivier
Centre Léon-Bérard, Lyon, France
Tubiana-Mathieu Nicole
Tubiana-Mathieu Nicole
Hôpital Dupuytren, Limoges, France

Industries

Voir plus
Novartis
35 collaboration(s)
Dernière en 2023
Lilly
17 collaboration(s)
Dernière en 2023
B3TSI
16 collaboration(s)
Dernière en 2023
AstraZeneca
16 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Essai Clinique (Seagen)   15 mars 2024
REPARP: Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Essai Clinique (Artios Pharma Ltd)   26 février 2024
StrateGlio: Phase III Randomised Trial Evaluating Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Essai Clinique (Centre Oscar-Lambret)   08 février 2024
LESS: Single-arm Study to De-escalate Adjuvant Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk of Metastasis
Essai Clinique (Agendia)   02 février 2024
The French National College of Oncology Teachers (CNEC): Missions, organization, and projects.
Bulletin du cancer   06 janvier 2024
DAISY: Phase II, Open Label Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC) for Advanced Breast Cancer Patients, With Biomarkers Analysis to Characterize Response/Resistance to Therapy
Essai Clinique (Daiichi Sankyo)   06 décembre 2023
TEDOVA: Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Essai Clinique (Merck & Co.)   04 décembre 2023
ACACIAS 3: Learning about announcement consultations in the second cycle of medical studies.
Bulletin du cancer   01 décembre 2023
Study of sarcopenia according to the criteria of mass, muscle strength and function, at the diagnosis of pancreatic cancer: impact on survival
Clinical nutrition ESPEN   01 décembre 2023
RIBOLARIS: Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer
Essai Clinique (Novartis)   06 octobre 2023